These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33350511)

  • 21. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs.
    Selmic LE; Ruple A
    BMC Vet Res; 2020 Jan; 16(1):5. PubMed ID: 31906934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mast cell tumor destruction by deionized water.
    Grier RL; Di Guardo G; Schaffer CB; Pedrosa B; Myers R; Merkley DF; Thouvenelle M
    Am J Vet Res; 1990 Jul; 51(7):1116-20. PubMed ID: 2117868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone.
    Smith J; Kiupel M; Farrelly J; Cohen R; Olmsted G; Kirpensteijn J; Brocks B; Post G
    Vet Comp Oncol; 2017 Mar; 15(1):36-45. PubMed ID: 25643820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional local therapy with primary re-excision or radiation therapy improves survival and local control after incomplete or close surgical excision of mast cell tumors in dogs.
    Kry KL; Boston SE
    Vet Surg; 2014 Feb; 43(2):182-9. PubMed ID: 24392683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
    Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE
    J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001).
    Gieger TL; Théon AP; Werner JA; McEntee MC; Rassnick KM; DeCock HE
    J Vet Intern Med; 2003; 17(5):687-92. PubMed ID: 14529136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of adjunctive radiation therapy for the treatment of mast cell tumors in dogs and assessment of toxicity: A multicenter observational study of 300 dogs.
    Mason SL; Pittaway C; Gil BP; Russak OM; Westlake K; Berlato D; Benoit J; Morris J; Dobson JM
    J Vet Intern Med; 2021 Nov; 35(6):2853-2864. PubMed ID: 34672378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999).
    Séguin B; Leibman NF; Bregazzi VS; Ogilvie GK; Powers BE; Dernell WS; Fettman MJ; Withrow SJ
    J Am Vet Med Assoc; 2001 Apr; 218(7):1120-3. PubMed ID: 11318363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marginal excision of cutaneous mast cell tumors in dogs was not associated with a higher rate of complications or prolonged wound healing than marginal excision of soft tissue sarcomas.
    Cockburn E; Janovec J; Solano MA; L'Eplattenier H
    J Am Vet Med Assoc; 2022 Jan; 260(7):741-746. PubMed ID: 35092664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of lateral surgical margins of up to two centimeters with margins of three centimeters for achieving tumor-free histologic margins following excision of grade I or II cutaneous mast cell tumors in dogs.
    Chu ML; Hayes GM; Henry JG; Oblak ML
    J Am Vet Med Assoc; 2020 Mar; 256(5):567-572. PubMed ID: 32068517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.
    Barnett CME; Broit N; Yap PY; Cullen JK; Parsons PG; Panizza BJ; Boyle GM
    Invest New Drugs; 2019 Feb; 37(1):1-8. PubMed ID: 29667135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting prognosis in canine subcutaneous mast cell tumors: 45 cases.
    Cherzan NL; Fryer K; Burke B; Farrelly J
    Vet Surg; 2023 May; 52(4):531-537. PubMed ID: 36788161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intralesional implant for treatment of primary oral malignant melanoma in dogs.
    Kitchell BE; Brown DM; Luck EE; Woods LL; Orenberg EK; Bloch DA
    J Am Vet Med Assoc; 1994 Jan; 204(2):229-36. PubMed ID: 8144382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
    Stanclift RM; Gilson SD
    J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
    Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
    J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998).
    Hahn KA; King GK; Carreras JK
    J Am Vet Med Assoc; 2004 Jan; 224(1):79-82. PubMed ID: 14710881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells.
    Matsuda A; Tanaka A; Amagai Y; Ohmori K; Nishikawa S; Xia Y; Karasawa K; Okamoto N; Oida K; Jang H; Matsuda H
    Vet Immunol Immunopathol; 2011 Dec; 144(3-4):321-8. PubMed ID: 21908058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs.
    Schultheiss PC; Gardiner DW; Rao S; Olea-Popelka F; Tuohy JL
    J Am Vet Med Assoc; 2011 Jun; 238(11):1464-9. PubMed ID: 21627510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs.
    Simpson AM; Ludwig LL; Newman SJ; Bergman PJ; Hottinger HA; Patnaik AK
    J Am Vet Med Assoc; 2004 Jan; 224(2):236-40. PubMed ID: 14736068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
    Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
    Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.